Using simvastatin to treat liver fibrosis caused by alcohol

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of simvastatin, a medication commonly used to lower cholesterol, in reducing liver fibrosis in patients suffering from advanced fibrosis due to chronic alcohol consumption. The study includes patients aged 18 and older who have been diagnosed with significant liver fibrosis, as determined by biopsy results. Participants will receive a daily dose of 40mg of simvastatin, and their liver health will be monitored throughout the trial to assess any improvements in fibrosis levels.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years
2. Chronic alcohol-related liver disease according to international guidelines (EASL, European Association for the Study of the Liver) and with data of significant liver fibrosis obtained in the diagnostic biopsy at the beginning of the study or in the last biopsy of the patient within 6 months prior to randomization. Significant liver fibrosis is defined by a score on the Ishak fibrosis scale of between 3 and 6.
3. Patients in the compensated chronic liver disease phase defined by the absence of clinical decompensations at the time of entering the study, with or without data of portal hypertension.
4. Women of childbearing potential must have a negative urine pregnancy test prior to study enrollment and agree to use highly effective contraceptive methods (combined oral pill, injectable or implanted contraceptive, intrauterine device / hormone delivery system intrauterine) during the study.

Exclusion Criteria:

1. Patients receiving statins or fibrates.
2. Patients with other etiologies of liver disease in addition to alcohol: hepatitis C, hepatitis B, autoimmune hepatitis, Wilson's disease, or hemochromatosis.
3. Patients in whom hepatitis C has been cured with antivirals in the 2 years prior to inclusion in the study.
4. Patients with a CK elevation of 50% or more above the upper limit of normal at the time of study inclusion.
5. Gastrointestinal bleeding due to portal hypertension within 12 months prior to inclusion in the study.
6. Clinical hepatic encephalopathy, defined as grade II-IV hepatic encephalopathy, in the 12 months prior to inclusion in the study.
7. Patients in need of diuretic treatment in the previous 12 months to control ascites or hydrothorax.
8. Spontaneous bacterial peritonitis within 12 months prior to study enrollment.
9. Hepatocellular carcinoma of any stage.
10. Patients with known muscle disease.
11. Patients with previous rhabdomyolysis.
12. Patients being treated with strong CYP3A4 enzyme inhibitors (see section 5.2: Concomitant drugs, not allowed and allowed).
13. Patients being treated with drugs with possible interactions with simvastatin (see section 5.2: Concomitant drugs, not allowed and allowed).
14. Patients with a history of significant extrahepatic disease with poor short-term prognosis, including New York Heart Association Grade III / V congestive heart failure, GOLD COPD\> 2, chronic kidney disease with serum creatinine\> 2mg / dL or under therapy of kidney replacement.
15. Patients with extrahepatic malignancies, including solid tumors and hematologic malignancies.
16. Patients with a history or increased risk of intestinal obstruction.
17. Pregnancy or breastfeeding.
18. Patients included in other clinical trials during the previous month.
19. Patients with mental disabilities, language barriers, poor social support or any other reason considered by the researcher as essential for adequate understanding, cooperation or compliance with the study.
20. Presence of data on alcoholic hepatitis in liver biopsy upon inclusion.
21. Patients with contraindications for statins.
22. Known hypersensitivity to simvastatin.
23. Refusal to sign the informed consent

Where it's running

• Jordi Gratacos
  Barcelona, Spain Recruiting

Study contacts

• Study coordinator: Gratacos
• Email: acruceta@recerca.clinic.cat
• Phone: 34 932275400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Endohepatology-based reclassification of treatment indication in high-risk MASLD

  This study tests whether an endohepatology assessment can change treatment decisions for adults with high-risk MASLD.

  Recruiting University Hospital Muenster · Münster · NCT07877272

• Umbilical cord stem cells added during Kasai to help biliary atresia

  This early-stage trial tests whether injecting umbilical cord mesenchymal stem cells during Kasai portoenterostomy is safe and helpful for infants with biliary atresia.

  Recruiting Phase 1 Dr Cipto Mangunkusumo General Hospital · Jakarta Pusat, DKI Jakarta · NCT07797673

• Effects of comorbidity on people with severe mental illness

  This study tests how having both alcohol/substance use and a severe mental illness affects hospitalizations, medications, and social participation among adults followed at a mental health center.

  Recruiting Abant Izzet Baysal University · Bolu, Bolu · NCT07692984

• Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD

  This program automatically screens high‑risk adults aged 50–75 in primary care to see if they have advanced liver fibrosis and possible MASLD, using routine blood tests and reflex lab tests without extra work for clinicians.

  Recruiting Hospital General Universitario Gregorio Marañon · Madrid, Madrid · NCT07658755

• AZD2389 safety and dosing in adults with fatty liver disease and advanced liver scarring

  This study tests whether AZD2389 is safe and how it behaves in adults with steatotic liver disease and advanced fibrosis, comparing it to placebo over about six months.

  Recruiting at 22 sites Phase 2 AstraZeneca · Chandler, Arizona and 21 other locations · NCT07610837

• See if EUS-SWQ can accurately detect and grade liver fibrosis in adults with chronic liver disease

  This study tests whether the endoscopic ultrasound shear wave quantification (EUS-SWQ) can match liver biopsy results in adults with chronic liver disease to diagnose and stage fibrosis, and whether it offers safety and measurement advantages over FibroScan.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07588854

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.